Akanda (NASDAQ:AKAN) Raised to “Sell” at Wall Street Zen

Akanda (NASDAQ:AKAN) was upgraded by Wall Street Zen from a “strong sell” rating to a “sell” rating in a report released on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Akanda in a research note on Thursday, August 13th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

Akanda Price Performance

Akanda stock opened at $1.98 on Friday. Akanda has a one year low of $1.94 and a one year high of $78.90. The company’s fifty day moving average price is $4.06 and its two-hundred day moving average price is $9.97.

Akanda (NASDAQ:AKAN) last issued its quarterly earnings data on Wednesday, September 30th. The company reported ($5.90) EPS for the quarter. The firm had revenue of $0.20 million during the quarter.

About Akanda

Akanda Corporation is an international medical cannabis company focused on the cultivation, processing, distribution and sale of cannabis products. Its activities have included medical cannabis flower, oils and other formulations intended for patients and healthcare markets.

The company has historically operated through businesses serving the European medical cannabis industry. Its operations have included cultivation and processing activities in Portugal, as well as CanMart, a United Kingdom-based importer and distributor of pharmaceutical-grade medical cannabis products.